

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2021

	30.09.2021	31.12.2020
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	37 016	37 123
Intangible assets	3 837	3 816
Assets with usable assets	84	210
Trade receivables	5 176	5 176
Total non-current assets	46 113	46 325
Current assets		
Inventories	9 651	10 842
Trade and other receivables	62 357	60 084
Current corporate income tax	-	14
Treasury shares redeemed	-	1
Cash and cash equivalents	36	45
Total current assets	72 044	70 986
Total assets	118 157	117 311
LIABILITIES		
Equity		
Share capital	84 500	82 200
Reserves	12 094	12 032
Retained earnings	4 059	2 904
Total	100 653	97 136
Non-current liabilities		
Long-term loans	1 921	1 731
Deferred tax liabilities	1 139	1 139
Retirement benefit obligations	194	194
Total non-current liabilities	3 254	3 064
Current liabilities		
Trade and other liabilities	3 989	6 583
Short-term loans	9 782	9 783
Current portion of long-term loans	363	541
Current corporate income tax		
Other tax liabilities	116	204
Total current liabilities	14 250	17 111
Total liabilities	17 504	20 175
Total equity and liabilities	118 157	117 311

Date of preparation: 28.10.2021

Sofia

Prepared by:.....

P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2021

	30.09.2021	30.09.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	34 901	32 665
Other income	22	54
Total income	34 923	32 719
Carrying amount of goods sold	(912)	(719)
Changes in inventories of finished products and work in progress	135	(397)
Materials and services	(22 975)	(20 437)
Personnel expenses	(4 059)	(3 475)
Depreciation / amortisation expenses	(2 960)	(3 169)
Other expenses	(360)	(137)
Finance income	14	52
Finance costs	(289)	(302)
Total expenses	(31 226)	(28 584)
Profit before taxation	3 697	4 135
Corporate income tax expense	(180)	(190)
Profit/Loss for the period	3 517	3 945
Total comprehensive income for the period	3 517	3 945
Earnings per share / in BGN per 1 share /	0.04	0.05

Date of preparation: 28.10.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2021

	30.09.2021	30.09.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	25 470	27 324
Payments to suppliers of materials, goods and services	(17 452)	(16 982)
Payments to personnel	(3 797)	(3 228)
Payments of interest and dividends	(166)	(332)
Other proceeds / payments	(2 471)	(3 523)
Net cash flows	1 584	3 259
Cash flows from investing activities		
Payments on non-current assets acquired	(1 093)	(2 655)
Net cash flows	(1 093)	(2 655)
Cash flows from financial activities		
Proceeds from loans	131	131
Payments on loans	(283)	(131)
Payment of interest, dividends	(20)	(147)
Payments on finance lease	(328)	(201)
Net cash flows	(500)	(348)
Change in cash and cash equivalents	(9)	256
Cash and cash equivalents at the beginning of the period	45	40
Cash and cash equivalents at the end of the period	36	296

Date of preparation: 28.10.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive


Director:.....


/ B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2021

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(11)		604	593
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
Total amount of income and expenses recognised during the period			268	(268)	
Balance as of 31.12.2020	82 200	4 088	7 944	2 904	97 136
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				3 517	3 517
Other comprehensive income					
Total comprehensive income				3 517	3 517
Issue of shares by the owners	2 300			(2 300)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			62	(62)	
Total amount of income and expenses recognised during the period	2 300		62	(2 362)	
Balance as of 30.09.2021	84 500	4 088	8 006	4 059	100 653

Date of preparation: 28.10.2021
Sofia

Prepared by: 
/P. Moneva/

Executive Director: 
/B. Georgiev /